UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer |
| |
| Authors: | Petrioli R Sabatino M Fiaschi A I Marsili S Pozzessere D Messinese S Correale P Civitelli S Tanzini G Tani F De Martino A Marzocca G Lorenzi M Giorgi G Francini G |
| |
| Affiliation: | Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy. |
| |
| Abstract: | A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2-73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand-foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC. |
| |
| Keywords: | colorectal cancer irinotecan oxaliplatin tegafur/uracil |
| 本文献已被 PubMed 等数据库收录！ |
